Scholarlink

<p>Congenital central hypoventilation syndrome (CCHS) is primarily caused by dominant <i>PHOX2B</i> mutations, with recessive <i>LBX1</i> or <i>MYO1H</i> mutations being rare. Among <i>PHOX2B</i> mutations, polyalanine repeat expansion mutations (PARMs) are common, whereas non-PARMs (NPARMs) are less frequent. <i>PHOX2B</i> mutations are believed to act through loss-of-function mechanisms combined with dominant-negative and/or toxic gain-of-function effects. However, the role of <i>PHOX2B</i> haploinsufficiency remains unclear. We investigated the role of <i>PHOX2B</i> deletion and other genetic modifiers in CCHS. Among 93 patients without <i>PHOX2B</i> mutations, four were found to carry <i>PHOX2B</i> deletions via multiplex ligation-dependent probe amplification. Two had typical CCHS, whereas two siblings presented with mild sleep hypoventilation following CCHS symptoms in infancy. After ruling out pathogenic variants in <i>LBX1</i> and <i>MYO1H</i>, we explored potential modifiers by analyzing sequence and methylation changes in the wild-type <i>PHOX2B</i> promoter and 3′ untranslated region (3′UTR), and the coding regions of <i>PHOX2A</i> and <i>MIR204</i>. One female patient with CCHS carried a 3′UTR haplotype predicted to reduce <i>PHOX2B</i> expression via <i>MIR204</i> interaction. To date, 15 informative cases with <i>PHOX2B</i> deletions (eight males, seven females) have been reported. Respiratory phenotypes included: CCHS (<i>n</i> = 5), CCHS with obstructive sleep apnea (OSA) (<i>n</i> = 1), OSA alone (<i>n</i> = 2), mild central sleep apnea (<i>n</i> = 1), mild central sleep hypoventilation or apnea following CCHS symptoms in infancy (<i>n</i> = 3), and asymptomatic (<i>n</i> = 3). These indicate that although a heterozygous <i>PHOX2B</i> deficiency alone is insufficient to cause CCHS, it may delay or impair the development of respiratory control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PHOX2B deletion in congenital central hypoventilation syndrome: is this sufficient for pathogenesis?

  • 期刊论文

  • 发表日期：

    2025年11月5日

查看全文
  • Kiyoshi Hayasaka,
  • Ayako Sasaki,
  • Yumiko Kishikawa,
  • Yu Abiko,
  • Haruka Arakaki,
  • Madoka Yasukohchi,
  • Jun Takayama,
  • Gen Tamiya,
  • Hisaya Hasegawa,
  • Atsushi Ueda,
  • Motoki Osawa,
  • Tetsuo Mitsui

摘要

Congenital central hypoventilation syndrome (CCHS) is primarily caused by dominant PHOX2B mutations, with recessive LBX1 or MYO1H mutations being rare. Among PHOX2B mutations, polyalanine repeat expansion mutations (PARMs) are common, whereas non-PARMs (NPARMs) are less frequent. PHOX2B mutations are believed to act through loss-of-function mechanisms combined with dominant-negative and/or toxic gain-of-function effects. However, the role of PHOX2B haploinsufficiency remains unclear. We investigated the role of PHOX2B deletion and other genetic modifiers in CCHS. Among 93 patients without PHOX2B mutations, four were found to carry PHOX2B deletions via multiplex ligation-dependent probe amplification. Two had typical CCHS, whereas two siblings presented with mild sleep hypoventilation following CCHS symptoms in infancy. After ruling out pathogenic variants in LBX1 and MYO1H, we explored potential modifiers by analyzing sequence and methylation changes in the wild-type PHOX2B promoter and 3′ untranslated region (3′UTR), and the coding regions of PHOX2A and MIR204. One female patient with CCHS carried a 3′UTR haplotype predicted to reduce PHOX2B expression via MIR204 interaction. To date, 15 informative cases with PHOX2B deletions (eight males, seven females) have been reported. Respiratory phenotypes included: CCHS (n = 5), CCHS with obstructive sleep apnea (OSA) (n = 1), OSA alone (n = 2), mild central sleep apnea (n = 1), mild central sleep hypoventilation or apnea following CCHS symptoms in infancy (n = 3), and asymptomatic (n = 3). These indicate that although a heterozygous PHOX2B deficiency alone is insufficient to cause CCHS, it may delay or impair the development of respiratory control.